Privileged structures in drug discovery : medicinal chemistry and synthesis

Content: Intro
 Title Page
 Copyright Page
 Contents
 Chapter 1 Introduction
 1.1 The Original Definition of Privileged Structures
 1.2 The Role of Privileged Structures in the Drug Discovery Process
 1.3 The Loose Definitions of â#x80
#x9C
Privileged Structuresâ#x80
#x9D

 1.4 Synthesis and Biological Activities of Carbocyclic and Heterocyclic Privileged Structures
 1.4.1 Synthesis and Biological Activities of Three- and Four-Membered Ring Privileged Structures
 1.4.2 Synthesis and Biological Activities of Five-Membered Ring Privileged Structures 1.4.3 Synthesis and Biological Activities of Six-Membered Ring Privileged Structures1.4.4 Synthesis and Biological Activities of Bicyclic 5/5 and 6/5 Ring Privileged Structures
 1.4.5 Synthesis and Biological Activities of Bicyclic 6/6 and 6/7 Ring Privileged Structures
 1.4.6 Synthesis and Biological Activities of Tricyclic and Tetracyclic Ring Privileged Structures
 1.5 Combinatorial Libraries of â#x80
#x9C
Privileged Structuresâ#x80
#x9D

 1.6 Scope of this Monograph
 References
 Chapter 2 Benzodiazepines
 2.1 Introduction
 2.2 Marketed BDZ Drugs
 2.2.1 1,4-Benzodiazepine Marketed Drugs 2.2.2 1,5-Benzodiazepine Marketed Drugs2.2.3 Linearly Fused BDZ Marketed Drugs
 2.2.4 Angularly Fused-1,4-Benzodiazepine Marketed Drugs
 2.3 Medicinal Chemistry Case Studies
 2.3.1 Cardiovascular Applications
 2.3.2 Central Nervous System Applications
 2.3.3 Gastrointestinal Applications
 2.3.4 Infectious Diseases Applications
 2.3.5 Inflammation Applications
 2.3.6 Metabolic Diseases Applications
 2.3.7 Oncology Applications
 2.4 Synthesis of BDZs
 2.4.1 Condensation of o-Phenylenediamines to 1,5-Benzodiazepines
 2.4.1.1 Condensation of o-Phenylenediamines with Ketones 2.4.1.2 Condensation of o-Phenylenediamines with α,β-Unsaturated Ketones2.4.1.3 Condensation of o-Phenylenediamines with Alkynes
 2.4.2 Reductive Condensation of α-Substituted Nitrobenzenes with Ketones and α,β-Unsaturated Ketones
 2.4.3 Intramolecular Cyclizations to 1,4-Benzodiazepines
 2.4.3.1 Intramolecular Cyclizationsâ#x80
#x94
Path A
 2.4.3.2 Intramolecular Cyclizationsâ#x80
#x94
Path B
 2.4.3.3 Intramolecular Cyclizationsâ#x80
#x94
Path C
 2.4.3.4 Intramolecular Cyclizationsâ#x80
#x94
Path D
 2.4.3.5 Intramolecular Cyclizationsâ#x80
#x94
Path E
 2.4.3.6 Intramolecular Cyclizationsâ#x80
#x94
Path F 2.4.3.7 Intramolecular Cyclizationsâ#x80
#x94
Path G2.4.3.8 Intramolecular Cyclizationsâ#x80
#x94
Path H
 2.4.4 Ugi Multicomponent Synthesis
 2.4.5 Elaboration of 1,4-Benzodiazepines
 2.4.6 Pyrrolo[2,1-c]benzodiazepines
 2.4.7 Fused BDZ Ring Systems
 2.4.8 Solid-Phase Synthesis of BDZs
 References
 Chapter 3 1,4-Dihydropyridines
 3.1 Introduction
 3.2 Marketed 1,4-Dihyropyridine Drugs
 3.3 Medicinal Chemistry Case Studies
 3.3.1 Cardiovascular Applications
 3.3.2 Central Nervous System Applications
 3.3.3 Infectious Diseases Applications
 3.3.4 Inflammation Applications 3.3.5 Menâ#x80
#x99
s and Womenâ#x80
#x99
s Health Issues Applications